Cardio- and cerebrovascular risk with conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS) in rheumatic arthritis (RA): a real-world comparative assesment
المؤلفون الرئيسيون: | Prats-Uribe, A, Illingens, B, Vizcaya, D, Weaver, J, Burn, E, Sawant, R, Marinier, K, Ryan, P, Prieto-Alhambra, D, European Hlth Data Evidence |
---|---|
التنسيق: | Conference item |
منشور في: |
2020
|
مواد مشابهة
-
Is Farming a Risk Occupation for Cardio-cerebrovascular Diseases? A Scoping Review on Cardio-cerebrovascular Disease Risk in Farmers
حسب: Hyeonjun Kim, وآخرون
منشور في: (2024-11-01) -
VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs
حسب: David Schub, وآخرون
منشور في: (2018-11-01) -
Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study
حسب: Naoki Iwamoto, وآخرون
منشور في: (2022-12-01) -
Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment
حسب: Caporali, R, وآخرون
منشور في: (2022) -
Mg alloy cardio-/cerebrovascular scaffolds: Developments and prospects
حسب: Shaokang Guan, وآخرون
منشور في: (2023-11-01)